Etoposide
Sold as P & u etoposide csv, Eposin, Etoposide hexal, Hx etoposide, Kemosid
(5S,5AR,8aR,9R)-5-[[(2R,4aR,6R,7R,8R,8aS)-7,8-dihydroxy-2-methyl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-6-yl]oxy]-9-(4-hydroxy-3,5-dimethoxyphenyl)-5a,6,8a,9-tetrahydro-5H-[2]benzofuro[6,5-f][1,3]benzodioxol-8-one
Drag to rotate. Structure from PubChem CID 36462.
Background
Registration
- Applicants
- 5
- Registrations
- 10
- Schedule source
- Consolidated Schedules 06 July 2026
Applicants and registrations
| Applicant | Brands | Dosages | Registrations | Schedule | Leaflets |
|---|---|---|---|---|---|
| Pfizer Laboratories (Pty) LtdCancelled | P & u etoposide csv | 100 mg / 5 ml | 300410 | S4 | None |
| Teva Pharmaceuticals (Pty) LtdCertificate held by Teva Pharmaceuticals (Pty) Ltd. | Eposin | 20 mg/ ml | 320263 | S4 | PIPIL |
| Sandoz South Africa (Pty) LtdCancelled | Etoposide hexal | 50 mg/2,5 ml -, 100 mg/5 ml - | 370169, 370170 | S4 | None |
| Oethmaan Biosims (Pty) Ltd | Hx etoposide | 000 mg/50 ml - 1, 50 mg/2,5 ml -, 100 mg/5 ML -, 200 mg/10 ML -, 400 mg/20 ml - | 370174, 370175, 370176, 370177, 370178 | S4 | None |
| Cipla Medpro (Pty) Ltd | Kemosid | 100 | A380387 | S4 | None |
Variants
| Product | Strength and form | Registration | Status | Schedule | Leaflets |
|---|---|---|---|---|---|
| P & u etoposide csv 100 MG / 5 ML injection EACH 1 ml SOLUTION CONTAINS ETOPOSIDE 20,0 mg | 100 mg / 5 mlInjection | 30041030/26/0410 | Cancelled | S4 | None |
| Eposin EACH 1,0 ML CONCENTRATE CONTAINS ETOPOSIDE 20,0 mg | 20 mg/ mlConcentrate for solution | 32026332/26/0263Approved 22 April 2024 | Registered | S4 | PIPIL |
| Etoposide - hexal 50 mg/2,5 ML EACH 2,5 ml SOLUTION CONTAINS ETOPOSIDE 50,0 mg | 50 mg/2,5 ml - | 37016937/34/0169 | Cancelled | S4 | None |
| Etoposide - hexal 100 mg/5 ML EACH 5,0 ml SOLUTION CONTAINS ETOPOSIDE 100,0 mg | 100 mg/5 ml - | 37017037/34/0170 | Cancelled | S4 | None |
| Hx - etoposide 50 mg/2,5 ML EACH 2,5 ml SOLUTION CONTAINS ETOPOSIDE 50,0 mg | 50 mg/2,5 ml - | 37017437/34/0174 | Registered | S4 | None |
| Hx - etoposide 100 mg/5 ML EACH 5,0 ml SOLUTION CONTAINS ETOPOSIDE 100,0 mg | 100 mg/5 ML - | 37017537/34/0175 | Registered | S4 | None |
| Hx - etoposide 200 mg/10 ML EACH 10,0 ml SOLUTION CONTAINS ETOPOSIDE 200,0 mg | 200 mg/10 ML - | 37017637/34/0176 | Registered | S4 | None |
| Hx - etoposide 400 mg/20 ML EACH 20,0 ml SOLUTION CONTAINS ETOPOSIDE 400,0 mg | 400 mg/20 ml - | 37017737/34/0177 | Registered | S4 | None |
| Hx - etoposide 1 000 mg/50 ML EACH 50,0 ML SOLUTION CONTAINS ETOPOSIDE 1000,0 mg | 000 mg/50 ml - 1 | 37017837/34/0178 | Registered | S4 | None |
| Kemosid 100 EACH 5,0 ml AMPOULE CONTAINS ETOPOSIDE 100,0 mg | 100 | A380387A38/26/0387 | Registered | S4 | None |
Regulatory status
Where S4 sits on the scale
Prescription-only medicine.
Schedule 4 covers most ordinary prescription medicines. You need a prescription from an authorised prescriber, such as a doctor or dentist, and a pharmacist dispenses it. Its price, name, pack size and strength can still be told to the public, as long as nothing links it to what it treats.
Schedule S4, matched to the Consolidated Schedules by ingredient, confidence high.
Who may supply: A pharmacist dispensing against a written or verbal prescription from an authorised prescriber; a veterinarian, who may also prescribe, compound or dispense it directly; a medical practitioner or dentist, who may prescribe it and may compound or dispense it directly only if licensed under section 22C(1)(a); manufacturers and wholesalers may supply people who may lawfully possess it; and, for animal treatment, a person practising a para-veterinary profession, on a veterinarian's written or verbal instruction.
Consolidated Schedules listings for Etoposide
S4: Etoposide
Consolidated Schedules 06 July 2026, line 6292
Pharmacological class: Cytostatic agents (class 26)
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
SAHPRA documents
Schedule Verification
Eposin, Teva Pharmaceuticals (Pty) Ltd is scheduled S4 in its official SAHPRA documents, read with 90% confidence.
These documents are provided by SAHPRA for informational purposes. Always consult with a healthcare professional for medical advice.